论文信息 - Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC) - 字舞流文

Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC)

E. Casper | R. Gralla | D. Kelsen | L. Itri | R. Golbey | R. Chapman

[1] C. Bloomfield,et al. Clinical trial of VP 16–213 (NSC 141540) I.V. Twice weekly in advanced neoplastic disease a study by the cancer and leukemia group B , 1980, Cancer.

[2] T. Fleming,et al. VP-16, Cyclophosphamide, Adriamycin and Cis-platinum (V:CAP-I) in Patients with Metastatic Adenocarcinoma of the Lung 1 , 1979, Tumori.

[3] J. Ingle,et al. VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung. , 1978, Cancer treatment reports.

[4] F. Cavalli,et al. A Combination of Cyclophosphamide, Methotrexate, Vincristine and VP 16–213 (NSC 141 540) in the Treatment of Bronchogenic Carcinoma , 1977, Tumori.

[5] J. Van Dyk,et al. A clinical trial of the oral form of 4′‐demethyl‐epipodophyllotoxin‐β‐D ethylidene glucoside (NSC 141540) VP 16–213 , 1975 .

[6] H. Stähelin,et al. Synthesis and antimitotic activity of glycosidic lignan derivatives related to podophyllotoxin. , 1971, Journal of medicinal chemistry.